Basilea News Basilea News en Tue, 06 Oct 2015 20:32:10 +0200 Tue, 06 Oct 2015 20:32:10 +0200 Chameleon CMS (Webmaster Webmaster) (Webmaster Webmaster) <![CDATA[Basilea announces development of inhaled dosage form of its Gram-negative antibiotic BAL30072 as part of European iABC program]]>
  • Start of "inhaled Antibiotics in Bronchiectasis and Cystic fibrosis" (iABC) program to develop new antibiotic treatments for cystic fibrosis and bronchiectasis
  • ]]>
    Mon, 07 Sep 2015 07:15:00 +0200
    <![CDATA[Basilea's Chief Technology Officer Dr. Ingrid Heinze-Krauss to retire and Dr. Günter Ditzinger named as successor]]> Fri, 28 Aug 2015 07:15:00 +0200 <![CDATA[Basilea reports 2015 half-year results - Major milestones achieved for CRESEMBA® and Zevtera®]]>
  • Antifungal CRESEMBA® (isavuconazole) received U.S. approval and is recommended for approval in the European Union
  • Antibiotic Zevtera®/Mabelio® (ceftobiprole medocaril) launched in four European countries
  • Ceftobiprole designated as a Qualified Infectious Disease Product for the treatment of lung and skin infections by U.S. FDA
  • Additional oncology program (panRAF kinase inhibitor BAL3833) entered phase 1 of clinical development
  • Cash and short-term investments of CHF 218.4 million
  • ]]>
    Fri, 14 Aug 2015 07:15:00 +0200
    <![CDATA[Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of lung and skin infections]]> Wed, 12 Aug 2015 07:15:00 +0200 <![CDATA[Basilea reports topline results of isavuconazole phase 3 study in candidemia and other invasive Candida infections]]> Thu, 30 Jul 2015 07:15:00 +0200 <![CDATA[Basilea announces that CHMP recommends approval of isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union]]> Fri, 24 Jul 2015 13:44:38 +0200 <![CDATA[Basilea initiates phase 1/2a oncology study with oral formulation of tumor checkpoint controller BAL101553]]> Thu, 25 Jun 2015 07:15:00 +0200 <![CDATA[Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor]]> Mon, 04 May 2015 19:38:45 +0200 <![CDATA[Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders]]> Wed, 29 Apr 2015 17:57:42 +0200 <![CDATA[Basilea reports isavuconazole and ceftobiprole data to be presented at ECCMID]]> Fri, 24 Apr 2015 07:15:00 +0200